Short Interest in Genprex (NASDAQ:GNPX) Expands By 69.7%

Genprex (NASDAQ:GNPX) saw a large growth in short interest during the month of August. As of August 14th, there was short interest totaling 62,590 shares, a growth of 69.7% from the July 30th total of 36,884 shares. Approximately 7.7% of the company’s shares are short sold. Based on an average daily volume of 391,029 shares, the short-interest ratio is presently 0.2 days.

Genprex Stock Up 1.1%

GNPX traded up $0.04 on Monday, reaching $3.71. 40,705 shares of the company traded hands, compared to its average volume of 91,217. Genprex has a one year low of $3.57 and a one year high of $1,210.00. The firm has a fifty day simple moving average of $7.71 and a two-hundred day simple moving average of $21.75. The company has a market cap of $3.04 million, a P/E ratio of -0.03 and a beta of -0.88.

Genprex (NASDAQ:GNPX) last issued its earnings results on Friday, August 14th. The company reported ($9.40) EPS for the quarter.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Mayflower Financial Advisors LLC purchased a new stake in shares of Genprex in the 1st quarter worth $36,000. Manchester Financial Inc. purchased a new position in shares of Genprex during the first quarter valued at $36,000. Finally, Susquehanna International Group LLP increased its stake in shares of Genprex by 11.7% during the third quarter. Susquehanna International Group LLP now owns 340,056 shares of the company’s stock valued at $58,000 after buying an additional 35,661 shares during the period. 14.05% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

GNPX has been the subject of several analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Genprex in a research note on Friday, July 17th. Wall Street Zen raised Genprex from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has a consensus rating of “Sell”.

Genprex Company Profile

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.